We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eco Animal Health Group Plc | LSE:EAH | London | Ordinary Share | GB0032036807 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 0.45% | 110.50 | 109.00 | 112.00 | 110.50 | 110.00 | 110.00 | 81,490 | 10:13:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chem,fertlizer Minrl Mng,nec | 85.31M | 1.01M | 0.0149 | 74.16 | 74.86M |
TIDMEAH
Eco Animal Health Group PLC
23 November 2021
RNS Reach
ECO Animal Health Group plc
("ECO" or "the Group")
(AIM: EAH)
Investor Presentation covering Interim Results
ECO Animal Health Group plc ("ECO" or "the Group"), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that Marc Loomes, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the Group's Interim Results for the period ended 30 September 2021.
The online presentation will take place on Tuesday 30th November at 11.00 am UK time. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.
To register for the event, please click here
Contacts:
ECO Animal Health Group plc Marc Loomes (CEO) Christopher Wilks (CFO) 020 8447 6906 IFC Advisory Graham Herring Zach Cohen 020 3934 6630 Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas 020 7496 3000 Peel Hunt LLP (Joint Broker) James Steel Dr Christopher Golden 020 7418 8900 E quity Development Hannah Crowe Matt Evans 020 7065 2692
About ECO Animal Health
ECO Animal Health Group plc ("ECO" or "the Group") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAZZMZMGZFGMZZ
(END) Dow Jones Newswires
November 23, 2021 02:00 ET (07:00 GMT)
1 Year Eco Animal Health Chart |
1 Month Eco Animal Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions